dc.creator | Vallejo Vaz, Antonio Javier | es |
dc.creator | Bray, Sarah | es |
dc.creator | Villa, Guillermo | es |
dc.creator | Brandts, Julia | es |
dc.creator | Kiru, Gaia | es |
dc.creator | Murphy, Jennifer | es |
dc.creator | Ray, Kausik K. | es |
dc.date.accessioned | 2023-04-18T12:58:00Z | |
dc.date.available | 2023-04-18T12:58:00Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | Vallejo Vaz, A.J., Bray, S., Villa, G., Brandts, J., Kiru, G., Murphy, J. y Ray, K.K. (2022). Implications of ACC/AHA Versus ESC/EAS LDL‑C Recommendations for Residual Risk Reduction in ASCVD: A Simulation Study From DA VINCI. Cardiovascular Drugs and Therapy. https://doi.org/10.1007/s10557-022-07343-x. | |
dc.identifier.issn | 0920-3206 | es |
dc.identifier.issn | 1573-7241 | es |
dc.identifier.uri | https://hdl.handle.net/11441/144586 | |
dc.description.abstract | Purpose Low-density lipoprotein cholesterol (LDL-C) recommendations difer between the 2018 American College of Cardi ology/American Heart Association (ACC/AHA) and 2019 European Society of Cardiology/European Atherosclerosis Society
(ESC/EAS) guidelines for patients with atherosclerotic cardiovascular disease (ASCVD) (<70 vs.<55 mg/dl, respectively).
In the DA VINCI study, residual cardiovascular risk was predicted in ASCVD patients. The extent to which relative and
absolute risk might be lowered by achieving ACC/AHA versus ESC/EAS LDL-C recommended approaches was simulated.
Methods DA VINCI was a cross-sectional observational study of patients prescribed lipid-lowering therapy (LLT) across 18
European countries. Ten-year cardiovascular risk (CVR) was predicted among ASCVD patients receiving stabilized LLT. For
patients with LDL-C≥70 mg/dl, the absolute LDL-C reduction required to achieve an LDL-C of<70 or<55 mg/dl (LDL-C
of 69 or 54 mg/dl, respectively) was calculated. Relative and absolute risk reductions (RRRs and ARRs) were simulated.
Results Of the 2039 patients, 61% did not achieve LDL-C<70 mg/dl. For patients with LDL-C≥70 mg/dl, median (inter quartile range) baseline LDL-C and 10-year CVR were 93 (81–115) mg/dl and 32% (25–43%), respectively. Median LDL-C
reductions of 24 (12–46) and 39 (27–91) mg/dl were needed to achieve an LDL-C of 69 and 54 mg/dl, respectively. Attaining
ACC/AHA or ESC/EAS goals resulted in simulated RRRs of 14% (7–25%) and 22% (15–32%), respectively, and ARRs of
4% (2–7%) and 6% (4–9%), respectively.
Conclusion In ASCVD patients, achieving ESC/EAS LDL-C goals could result in a 2% additional ARR over 10 years ver sus the ACC/AHA approa. | es |
dc.format | application/pdf | es |
dc.format.extent | 13 p. | es |
dc.language.iso | eng | es |
dc.publisher | Springer | es |
dc.relation.ispartof | Cardiovascular Drugs and Therapy. | |
dc.rights | Atribución 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | Atherosclerotic cardiovascular disease | es |
dc.subject | LDL-C | es |
dc.subject | Lipid-lowering | es |
dc.subject | Statins | es |
dc.subject | Cardiovascular risk | es |
dc.subject | Cardiovascular disease prevention | es |
dc.title | Implications of ACC/AHA Versus ESC/EAS LDL‑C Recommendations for Residual Risk Reduction in ASCVD: A Simulation Study From DA VINCI | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.relation.publisherversion | https://link.springer.com/article/10.1007/s10557-022-07343-x | es |
dc.identifier.doi | 10.1007/s10557-022-07343-x | es |
dc.journaltitle | Cardiovascular Drugs and Therapy | es |